Common heart drug may shield eyes of type 1 diabetes patients
NCT ID NCT01320345
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether fenofibrate, a drug typically used to lower blood fats, can slow the worsening of diabetic retinopathy (eye damage) in adults with type 1 diabetes. Over 400 participants take either fenofibrate or a placebo daily for three years. The goal is to see if the drug reduces the need for laser surgery or other eye treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fenofibrate (a drug that lowers fats in the blood)
What this could lead to
If it works, fenofibrate could become a new way to slow or prevent vision loss from diabetic retinopathy in people with type 1 diabetes.
What could go wrong
This is a phase 3 trial, but results are not yet reported. Fenofibrate may not slow retinopathy enough to be useful, and it can cause side effects like muscle pain or liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland Diabetes Centre
Auckland, 1051, New Zealand
-
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004, Australia
-
Belfast Health and Social Care Trust
Belfast, BT12 6BA, United Kingdom
-
Cairns Hospital
Cairns, Queensland, 4870, Australia
-
Canberra Hospital
Garran, Australian Capital Territory, 2605, Australia
-
Christchurch Hospital
Christchurch, 8011, New Zealand
-
Concord Repatriation General Hospital
Concord, New South Wales, 2139, Australia
-
Fremantle Hospital
Fremantle, Western Australia, 6160, Australia
-
Garvan Institute of Medical Research
Darlinghurst, New South Wales, 2010, Australia
-
Heidelberg Repatriation Hospital
Heidelberg, Victoria, 3081, Australia
-
Hunter Diabetes Centre
Merewether, New South Wales, 2291, Australia
-
Mater Adult Hospital
South Brisbane, Queensland, 4101, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, 2032, Australia
-
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Retina Associates - South West Retina
Liverpool, New South Wales, 2170, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal North Shore Hospital
Saint Leonards, New South Wales, 2065, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
Southern Adelaide Diabetes and Endocrine Services
Oaklands Park, South Australia, 5046, Australia
-
St Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
-
Sunshine Hospital
St Albans, Victoria, 3021, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
University Hospital Geelong
Geelong, Victoria, 3220, Australia